Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.


Monthly Webinar Series - January

Pro/Con Debate:
Eosinophils are the Key Inflammatory Driver in Severe Asthma

Wednesday, 11 January 2023
9:30 am - 11:00 am US Eastern
3:30 pm - 5:00 pm Central Europe

Register Now


Sponsored by:


Webinar Program

9:30 am – 9:35 am:  Welcome & Intros
Moderator: Praveen Akuthota, MD

9:35 am – 9:55 am:  Pro Opening Statement
Ian Pavord, MA DM FRCP FERS FMedSci

9:55 am – 10:15 am:  Con Opening Statement
Michael Wechsler, MD, MMSc

10:15 am – 10:20 am::  Pro Rebuttal/Conclusions 
Ian Pavord, MA DM FRCP FERS FMedSci

10:20 am – 10:25 am:  Con Rebuttal/Conclusions 
Michael Wechsler, MD, MMSc

10:25 am – 10:55 am: Audience Q&A and Voting/Poll

10:55 am – 11:00 am: Closing Remarks 

Moderator: Praveen Akuthota, MD


Ian Pavord, MA DM FRCP FERS FMedSci

A Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals. He is a member of congregation at the University of Oxford and a Professorial Fellow of St Edmund Hall. He was a Consultant Physician from 1995 and Honorary Professor of Medicine from 2005 to 2013 at the Institute for Lung Health, Glenfield Hospital, University Hospitals of Leicester NHS Trust. He was elected an NIHR Senior Investigator in 2011&14, an inaugural Fellow of the European Respiratory Society in 2014 and a Fellow of the Academy of Medical Science in 2015.


Michael Wechsler, MD, MMSc

A Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at NJH in Denver, Director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and Associate Vice President for Innovation and Industry Relations at NJH. In addition to clinical work in pulmonary & critical care medicine, Professor Wechsler’s research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome, CSS). He has led studies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab. He has published more than 250 peer-reviewed manuscripts relating to asthma, EGPA and eosinophilic lung diseases. 


Last updated: November 30, 2022

Corporate Advisory Council

AllakosAmgenAstra Zeneca

CelldexGSKSanofi Regeneron